Analysis from the EMPA-REG OUTCOME® trial indicates empagliflozin may assist in preventing the progression of chronic kidney disease in patients with type 2 diabetes irrespective of medications that alter intrarenal hemodynamics

Kidney International

Volumn 96, Issue 2, 2019, Pages 489-504

  Mayer, Gert J ^a   Wanner, Christoph ^b   Weir, Matthew R ^c   Inzucchi, Silvio E ^d   Koitka Weber, Audrey ^b,e,f   Hantel, Stefan ^e   von Eynatten, Maximilian ^e   Zinman, Bernard ^g   Cherney, David Z I ^h  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^f MONASH UNIVERSITY   (Australia)

^g MOUNT SINAI HOSPITAL   (Canada)

^h UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

ACEis; CKD; CV disease; diuretics; sodium glucose cotransporter 2 inhibitors; type 2 diabetes

Indexed keywords

EMPAGLIFLOZIN; PLACEBO; BENZHYDRYL DERIVATIVE; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLUCOSIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PROTECTIVE AGENT;

ACUTE KIDNEY FAILURE; ARTICLE; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG SAFETY; EDEMA; GENITAL TRACT INFECTION; HUMAN; HYPERKALEMIA; HYPOKALEMIA; INCIDENCE; KIDNEY BLOOD FLOW; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; RISK REDUCTION; SIDE EFFECT; URINARY TRACT INFECTION; ADMINISTRATION AND DOSAGE; ADULT; BLOOD FLOW; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMORBIDITY; COMPLICATION; DIABETIC NEPHROPATHY; DRUG EFFECT; FEMALE; GLOMERULUS FILTRATION RATE; KIDNEY; MALE; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PATHOPHYSIOLOGY; PHASE 3 CLINICAL TRIAL; PHYSIOLOGY; VASCULARIZATION;

ADULT; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BENZHYDRYL COMPOUNDS; CALCIUM CHANNEL BLOCKERS; CARDIOVASCULAR DISEASES; COMORBIDITY; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; DIURETICS; FEMALE; GLOMERULAR FILTRATION RATE; GLUCOSIDES; HUMANS; KIDNEY; MALE; MIDDLE AGED; PROTECTIVE AGENTS; REGIONAL BLOOD FLOW; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS;

EID: 85066077881     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1016/j.kint.2019.02.033     Document Type: Article

References (40)

1. Wanner, C., Inzucchi, S.E., Lachin, J.M., et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 375 (2016), 323–334.
2. Zinman, B., Wanner, C., Lachin, J.M., et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373 (2015), 2117–2128.
3. Neal, B., Perkovic, V., Mahaffey, K.W., et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377 (2017), 644–657.
4. Wiviott, S.D., Raz, I., Bonaca, M.P., et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 380 (2019), 347–357.
5. Heerspink, H.J., Perkins, B.A., Fitchett, D.H., et al. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation 134 (2016), 752–772.
6. Zinman, B., Inzucchi, S.E., Lachin, J.M., et al. Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME). Cardiovasc Diabetol, 13, 2014, 102.
7. Cherney, D.Z.I., Zinman, B., Inzucchi, S.E., et al. Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial. Lancet Diabetes Endocrinol 5 (2017), 610–621.
8. Wanner, C., Lachin, J.M., Inzucchi, S.E., et al. Empagliflozin and clinical outcomes in patients with type 2 diabetes mellitus, established cardiovascular disease, and chronic kidney disease. Circulation 137 (2018), 119–129.
9. Neuen, B.L., Ohkuma, T., Neal, B., et al. Cardiovascular and renal outcomes with canagliflozin according to baseline kidney function. Circulation 138 (2018), 1537–1550.
10. Cherney, D.Z., Perkins, B.A., Soleymanlou, N., et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 129 (2014), 587–597.
11. Thomson, S.C., Rieg, T., Miracle, C., et al. Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat. Am J Physiol Regul Integr Comp Physiol 302 (2012), R75–R83.
12. Vallon, V., Gerasimova, M., Rose, M.A., et al. SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice. Am J Physiol Renal Physiol 306 (2014), F194–F204.
13. Gembardt, F., Bartaun, C., Jarzebska, N., et al. The SGLT2 inhibitor empagliflozin ameliorates early features of diabetic nephropathy in BTBR ob/ob type 2 diabetic mice with and without hypertension. Am J Physiol Renal Physiol 307 (2014), F317–F325.
14. Kidokoro K, Cherney DZI, Bozovic A, et al. Evaluation of glomerular hemodynamic function by empagliflozin in diabetic mice using in vivo imaging [e-pub ahead of print]. Circulation. https://doi.org/10.1161/CIRCULATIONAHA.118.037418. Accessed February 19, 2019.
15. Anderson, S., Jung, F.F., Ingelfinger, J.R., Renal renin-angiotensin system in diabetes: functional, immunohistochemical, and molecular biological correlations. Am J Physiol 265 (1993), F477–F486.
16. Perico, N., Amuchastegui, C.S., Malanchini, B., et al. Angiotensin-converting enzyme inhibition and calcium channel blockade both normalize early hyperfiltration in experimental diabetes, but only the former prevents late renal structural damage. Exp Nephrol 2 (1994), 220–228.
17. Sochett, E.B., Cherney, D.Z., Curtis, J.R., et al. Impact of renin angiotensin system modulation on the hyperfiltration state in type 1 diabetes. J Am Soc Nephrol 17 (2006), 1703–1709.
18. Fabris, B., Candido, R., Armini, L., et al. Control of glomerular hyperfiltration and renal hypertrophy by an angiotensin converting enzyme inhibitor prevents the progression of renal damage in hypertensive diabetic rats. J Hypertens 17 (1999), 1925–1931.
19. Zatz, R., Dunn, B.R., Meyer, T.W., et al. Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest 77 (1986), 1925–1930.
20. Nasrallah, R., Robertson, S.J., Hebert, R.L., Chronic COX inhibition reduces diabetes-induced hyperfiltration, proteinuria, and renal pathological markers in 36-week B6-Ins2(Akita) mice. Am J Nephrol 30 (2009), 346–353.
21. Komers, R., Lindsley, J.N., Oyama, T.T., et al. Immunohistochemical and functional correlations of renal cyclooxygenase-2 in experimental diabetes. J Clin Invest 107 (2001), 889–898.
22. Ohno, S., Yokoi, H., Mori, K., et al. Ablation of the N-type calcium channel ameliorates diabetic nephropathy with improved glycemic control and reduced blood pressure. Sci Rep, 6, 2016, 27192.
23. Chagnac, A., Herman, M., Zingerman, B., et al. Obesity-induced glomerular hyperfiltration: its involvement in the pathogenesis of tubular sodium reabsorption. Nephrol Dial Transplant 23 (2008), 3946–3952.
24. Heise, T., Mattheus, M., Woerle, H.J., et al. Assessing pharmacokinetic interactions between the sodium glucose cotransporter 2 inhibitor empagliflozin and hydrochlorothiazide or torasemide in patients with type 2 diabetes mellitus: a randomized, open-label, crossover study. Clin Ther 37 (2015), 793–803.
25. Komlosi, P., Fintha, A., Bell, P.D., Unraveling the relationship between macula densa cell volume and luminal solute concentration/osmolality. Kidney Int 70 (2006), 865–871.
26. Balen, D., Ljubojevic, M., Breljak, D., et al. Revised immunolocalization of the Na+-D-glucose cotransporter SGLT1 in rat organs with an improved antibody. Am J Physiol Cell Physiol 295 (2008), C475–C489.
27. Peti-Peterdi, J., Harris, R.C., Macula densa sensing and signaling mechanisms of renin release. J Am Soc Nephrol 21 (2010), 1093–1096.
28. Weber, M.A., Mansfield, T.A., Cain, V.A., et al. Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Diabetes Endocrinol 4 (2016), 211–220.
29. Rahman, A., Kittikulsuth, W., Fujisawa, Y., et al. Effects of diuretics on sodium-dependent glucose cotransporter 2 inhibitor-induced changes in blood pressure in obese rats suffering from the metabolic syndrome. J Hypertens 34 (2016), 893–906.
30. Devineni, D., Vaccaro, N., Polidori, D., et al. Effects of hydrochlorothiazide on the pharmacokinetics, pharmacodynamics, and tolerability of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in healthy participants. Clin Ther 36 (2014), 698–710.
31. Ando, K., L-/N-type calcium channel blockers and proteinuria. Curr Hypertens Rev 9 (2013), 210–218.
32. Seino, H., Miyaguchi, S., Yamazaki, T., et al. Effect of benidipine hydrochloride, a long-acting T-type calcium channel blocker, on blood pressure and renal function in hypertensive patients with diabetes mellitus: analysis after switching from cilnidipine to benidipine. Arzneimittelforschung 57 (2007), 526–531.
33. Fogari, R., Corradi, L., Zoppi, A., et al. Addition of manidipine improves the antiproteinuric effect of candesartan in hypertensive patients with type II diabetes and microalbuminuria. Am J Hypertens 20 (2007), 1092–1096.
34. Fujisawa, T., Ikegami, H., Noso, S., et al. Renoprotective effect of N-type Ca channel blockade in diabetic nephropathy. J Diabetes Complications 21 (2007), 252–257.
35. Cherney, D.Z., Scholey, J.W., Miller, J.A., Insights into the regulation of renal hemodynamic function in diabetic mellitus. Curr Diabetes Rev 4 (2008), 280–290.
36. Cherney, D.Z., Miller, J.A., Scholey, J.W., et al. The effect of cyclooxygenase-2 inhibition on renal hemodynamic function in humans with type 1 diabetes. Diabetes 57 (2008), 688–695.
37. Heyman, S.N., Khamaisi, M., Rosen, S., et al. Potential hypoxic renal injury in patients with diabetes on SGLT2 inhibitors: caution regarding concomitant use of NSAIDs and iodinated contrast media. Diabetes Care 40 (2017), e40–e41.
38. Szalat, A., Perlman, A., Muszkat, M., et al. Can SGLT2 inhibitors cause acute renal failure? Plausible role for altered glomerular hemodynamics and medullary hypoxia. Drug Safety 41 (2018), 239–252.
39. Nadkarni, G.N., Ferrandino, R., Chang, A., et al. Acute kidney injury in patients on SGLT2 inhibitors: a propensity-matched analysis. Diabetes Care 40 (2017), 1479–1485.
40. Desai, M., Yavin, Y., Balis, D., et al. Renal safety of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus. Diabetes Obes Metab 19 (2017), 897–900.